The FDA approved Hibsago (bepirovirsen; GSK), the first antisense oligonucleotide for chronic hepatitis B, for use with a nucleos (t)ide analogue in adults without cirrhosis, the agency announced ...
FDA approves Hibsago (bepirovirsen) with NrtI therapy for adult chronic hepatitis B without cirrhosis; phase 3 trials show up to 20% functional cure at 72 weeks.
GSK’s bepirovirsen (Hibsago) has secured FDA approval for the treatment of chronic hepatitis B virus (HBV), when used with existing antiviral therapy in adults without cirrhosis. “This is the start of ...
The FDA approved bepirovirsen as the first antisense oligonucleotide for chronic hepatitis B virus infection, alongside existing antiviral therapy for eligible adults without cirrhosis. Bepirovirsen ...
Mens Fitness on MSN
FDA Approves Hibsago, a Hepatitis B Treatment That Could Let Some Patients Stop Therapy
FDA-approved Hibsago could help some adults with chronic hepatitis B stop antiviral therapy. Learn who qualifies, what trials found, and the key risks.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results